Treating these sarcoma tumors with the CDK4 inhibitor palbociclib revealed that tumors expressing high levels of CDK4 mRNA, but not those expressing low CDK4 and high p16INK4a levels, responded to palbociclib. The gene discussed is CDKN2A; the disease is sarcoma.